Activists challenge U.S.-Gilead R&D pact, exposing patent-driven inequities in global HIV prevention access
Original framing: “STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents” — STAT News
The current patent dispute echoes the early AIDS activism of the 1980s, where activists forced pharmaceutical firms to lower prices and increase transparency. It also mirrors colonial patterns where Western entities controlled medical supplies in the Global South, perpetuating dependency. Understanding these continuities reveals the entrenched nature of profit‑driven health governance.
The Biden‑Gilead R&D pact exemplifies a recurring pattern where patent law, corporate profit, and state policy intersect to marginalise the very communities most affected by HIV.
Historical activism, cross‑cultural successes, and indigenous health frameworks reveal viable alternatives that decouple innovation from exclusivity. By embedding scientific evidence, future modelling, and trickster insights into policy, stakeholders—including governments, NGOs, and community leaders—can construct a patent pool and conditional funding mechanisms that guarantee affordable access. Elevating marginalised voices and artistic‑spiritual expressions ensures that solutions are not only technically sound but also socially resonant, paving the way for a globally equitable HIV prevention landscape.